|
|
|
|
|
26.08.25 - 08:36
|
Novartis: Deal mit skandinavischen Biotech – Aktie startet durch (Der Aktionaer)
|
|
|
Der Pharma-Riese Novartis geht eine weitere Forschungskooperation ein. Mit dem schwedischen Unternehmen BioArctic, dem eigentlichen Entdecker des Alzheimer-Medikaments Leqembi (Lecanemab), soll zunächst ein neuer Wirkstoffkandidat entwickelt werden. Die Skandinavier holen sich damit nach Eisai und Bristol Myers Squibb einen weiteren Pharma-Giganten als Partner ins Boot....
|
|
|
|
|
|
|
|
|
25.08.25 - 09:33
|
Leqembi® (lecanemab) launched in the EU today (PR Newswire)
|
|
|
STOCKHOLM, Aug. 25, 2025 /PRNewswire/ --BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the launch of Leqembi in the EU started in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025. Leqembi received the European Commission......
|
|
|
25.08.25 - 09:30
|
Leqembi® (lecanemab) launched in the EU today (PR Newswire)
|
|
|
STOCKHOLM, Aug. 25, 2025 /PRNewswire/ --BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the launch of Leqembi in the EU started in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025. Leqembi received the European Commission......
|
|
|
|
|
21.08.25 - 09:01
|
Invitation to presentation of BioArctic′s second quarter report for April – June 2025 on August 28 at 9.30 a.m. CET (Cision)
|
|
|
Stockholm, Sweden, August 21, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's second quarter report for April – June 2025 on Thursday, August 28, 2025, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on August 28, at 09:30 CET, where Gunilla Osswald, CEO, Anders Martin-Löf, CFO, and colleagues will present and comment on the second quarter report, followed by a Q&A-session.
If you wish to participate via webcast, please use the link below. Via the webcast you...
|
|
|
|
|
|
|
|
|
|
|
31.07.25 - 01:36
|
Latest data presented at AAIC 2025 reinforces lecanemab′s clinical effect with consistent safety profile (Cision)
|
|
|
Stockholm, Sweden, July 31, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC), held in Toronto, July 27 to 31. The presentations included four-year treatment data from the phase 3 Clarity AD open-label extension study, data on subcutaneous dosing and interim data from an ongoing real-world evidence study. The data further reinforces the clinical efficacy of lecanemab, with a safety profile in line with the phase 3 Clarity AD core study results.
1. Four...
|
|
|
|
|
|
|
|
|
|
|
|
|
26.06.25 - 10:18
|
Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize (Cision)
|
|
|
Stockholm, Sweden, June 26, 2025– BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering contributions to the understanding of Alzheimer's disease and to the development of the drug lecanemab. The prize is presented jointly by German Center for Neurodegenerative Diseases (DZNE) and the Piepenbrock Group. The award ceremony will take place in Bonn in November this year.
"I'm proud to have been awarded the 2025 Hartwig Piepenbrock-DZNE Prize. Being able to give...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
